Motosugi Utaroh, Bannas Peter, Bookwalter Candice A, Sano Katsuhiro, Reeder Scott B
From the Departments of Radiology (U.M., P.B., C.A.B., S.B.R.), Medical Physics (S.B.R.), Biomedical Engineering (S.B.R.), Medicine (S.B.R.), and Emergency Medicine (S.B.R.), University of Wisconsin, 600 Highland Ave, Madison, WI 53792-3252; Department of Radiology, University of Yamanashi, Yamanashi, Japan (U.M., K.S.); and Department of Radiology, University Hospital Hamburg-Eppendorf, Hamburg, Germany (P.B.).
Radiology. 2016 Apr;279(1):93-102. doi: 10.1148/radiol.2015150642. Epub 2015 Oct 16.
To investigate the cause of imaging artifacts observed during gadoxetic acid-enhanced arterial phase imaging of the liver.
This HIPAA-compliant study was approved by the institutional review board. Data were collected prospectively at two sites (site A, United States; site B, Japan) from patients undergoing contrast material-enhanced MR imaging with gadoxetic acid (site A, n = 154, dose = 0.05 mmol/kg; site B, n = 130, 0.025 mmol/kg) or gadobenate dimeglumine (only site A, n = 1666) from January 2014 to September 2014 at site A and from November 2014 to January 2015 at site B. Detailed comparisons between the two agents were made in the patients with dynamic liver acquisitions (n = 372) and age-, sex-, and baseline oxygen saturation (Spo2)-matched pairs (n = 130) at site A. Acquired data included self-reported dyspnea after contrast agent injection, Spo2, and breath-hold fidelity monitored with respiratory bellows.
Self-reported dyspnea was more frequent with gadoxetic acid than with gadobenate dimeglumine (site A, 6.5% [10 of 154] vs 0.1% [two of 1666], P < .001; site B, 1.5% [two of 130]). In the matched-pair comparison, gadoxetic acid, as compared with gadobenate dimeglumine, had higher breath-hold failure rates (site A, 34.6% [45 of 130] vs 11.7% [15 of 130], P < .0001; site B, 16.2% [21 of 130]) and more severe artifacts during arterial phase imaging (site A, 7.7% [10 of 130] vs 0% [none of 130], P < .001; site B, 2.3% [three of 130]). Severe imaging artifacts in patients who received gadoxetic acid were significantly associated with male sex (P = .023), body mass index (P = .021), and breath-hold failure (P < .001) but not with dyspnea or Spo2 decrease.
Severe motion-related artifacts in the arterial phase of gadoxetic acid-enhanced liver MR imaging are associated with breath-hold failure but not with subjective feelings of dyspnea or a substantial decrease in blood Spo2. Subjective feelings of dyspnea are not necessarily associated with imaging artifacts. The phenomenon, albeit at a lower rate, was confirmed at a second site in Japan.
探讨钆塞酸增强肝脏动脉期成像时观察到的成像伪影的原因。
本符合健康保险流通与责任法案(HIPAA)的研究经机构审查委员会批准。前瞻性收集了两个地点(地点A,美国;地点B,日本)的数据,这些数据来自2014年1月至9月在地点A以及2014年11月至2015年1月在地点B接受钆塞酸(地点A,n = 154,剂量 = 0.05 mmol/kg;地点B,n = 130,0.025 mmol/kg)或钆贝葡胺(仅地点A,n = 1666)增强磁共振成像的患者。在地点A对动态肝脏采集患者(n = 372)以及年龄、性别和基线氧饱和度(Spo2)匹配的配对患者(n = 130)进行了两种对比剂之间的详细比较。采集的数据包括对比剂注射后自我报告的呼吸困难、Spo2以及用呼吸波纹管监测的屏气保真度。
钆塞酸组自我报告的呼吸困难比钆贝葡胺组更频繁(地点A,6.5%[154例中的10例]对0.1%[1666例中的2例],P <.001;地点B,1.5%[130例中的2例])。在配对比较中,与钆贝葡胺相比,钆塞酸的屏气失败率更高(地点A,34.6%[130例中的45例]对11.7%[130例中的15例]),P <.0001;地点B,16.2%[130例中的21例]),并且在动脉期成像时伪影更严重(地点A,7.7%[130例中的10例]对0%[130例中无],P <.001;地点B,2.3%[130例中的3例])。接受钆塞酸的患者中严重成像伪影与男性性别(P =.023)、体重指数(P =.021)和屏气失败(P <.001)显著相关,但与呼吸困难或Spo2降低无关。
钆塞酸增强肝脏磁共振成像动脉期严重的运动相关伪影与屏气失败有关,但与主观呼吸困难感觉或血液Spo2的大幅降低无关。主观呼吸困难感觉不一定与成像伪影相关。该现象在日本的第二个地点也得到了证实,尽管发生率较低。